Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta (PDE6D, also known as PDEδ) is a highly conserved, non-catalytic subunit of the PDE6 complex that functions primarily as a cytosolic trafficking chaperone for prenylated (farnesylated or geranylgeranylated) proteins. By binding the lipidated C-termini of cargo proteins within its hydrophobic pocket, PDE6D solubilizes them in the aqueous cytoplasm, facilitating their diffusion and proper localization to cellular membranes, such as the plasma membrane or primary cilia. Key cargo proteins of PDE6D include Ras family GTPases (such as KRAS, NRAS, and Rheb) and ciliary proteins (such as INPP5E).
In oncology, PDE6D has emerged as a prominent surrogate therapeutic target for KRAS-mutant cancers, such as pancreatic, colorectal, and lung cancers, where KRAS membrane localization is essential for oncogenic signaling. Small-molecule inhibitors (e.g., Deltarasin, Deltazinone, and Deltasonamides) and targeted protein degraders (PROTACs and molecular glues) have been developed to block the prenyl-binding pocket or induce PDE6D degradation, thereby mislocalizing KRAS to endomembranes and suppressing downstream MAPK/ERK and PI3K/AKT pathways. However, therapeutic challenges remain, including the broad cargo spectrum of PDE6D which can lead to off-target toxicities, and its critical role in ciliary trafficking, where genetic loss of function is associated with ciliopathies like Joubert syndrome.
Inhibition of the prenyl-binding pocket, targeted protein degradation, molecular glue-mediated degradation, or stabilization of the KRAS-PDE6D complex
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta (PDE6D) (PDE6D).